{"id":"95fde5f3-20b2-53a9-946b-b87fb5ff9f26","stable_key":"220adaab-10d8-5c4e-a3f5-a48700ea794d:agmatine-sulfate-oral-clinical","predicate":"associated_with_improvement","statement":"A randomized trial of 2.670 g/day oral agmatine sulfate for 14 days reported greater pain and quality-of-life improvements than placebo; 51 and 48 were randomized, but 31 and 30 were analyzed.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"80c495bc-5fd8-5d67-b12d-a8bfb69dcfcf","mechanism_event_label":"There is limited human outcome evidence, with substantial attrition to consider.","subject":{"id":"ae2dddf4-ce04-57e3-8a06-7ed9fdc24554","slug":"agmatine-sulfate","display_name":"Agmatine Sulfate","entity_type_key":"small_molecule"},"object":{"id":"f7909127-9ebc-5381-9eca-c75b71cc6ff2","slug":"human-agmatine-sulfate-radiculopathy-outcomes","display_name":"Human radiculopathy outcomes after agmatine sulfate","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"80c495bc-5fd8-5d67-b12d-a8bfb69dcfcf","stable_key":"220adaab-10d8-5c4e-a3f5-a48700ea794d:agmatine-sulfate-oral-clinical-event","event_type":"observed_relationship","label":"There is limited human outcome evidence, with substantial attrition to consider.","description":"A randomized trial of 2.670 g/day oral agmatine sulfate for 14 days reported greater pain and quality-of-life improvements than placebo; 51 and 48 were randomized, but 31 and 30 were analyzed.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ae2dddf4-ce04-57e3-8a06-7ed9fdc24554","slug":"agmatine-sulfate","display_name":"Agmatine Sulfate","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"f7909127-9ebc-5381-9eca-c75b71cc6ff2","slug":"human-agmatine-sulfate-radiculopathy-outcomes","display_name":"Human radiculopathy outcomes after agmatine sulfate","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"e2f83eb4-99ed-5050-87d3-3e4701d05c1a","slug":"agmatine","display_name":"Agmatine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"3634af03-823b-584f-8e8e-e6ab6e3fbb60","slug":"sulfate","display_name":"Sulfate / SO4(2-)","entity_type_key":"ion"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Lumbar disc-associated radiculopathy; double-blind placebo-controlled trial after dose escalation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Short exposure and reduced analyzed sample limit inference; molecular mediation and general chronic-pain efficacy were not established.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Agmatine Sulfate collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"agmatine-sulfate","display_name":"Agmatine Sulfate","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"There is limited human outcome evidence, with substantial attrition to consider.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20447305/ · DOI 10.1111/j.1526-4637.2010.00808.x","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"541e9b80-bd8f-52a9-992a-7cc10eaf91a2","evidence_kind":"source_excerpt","locator":"Lines 436-442","start_line":436,"end_line":442,"excerpt":"## agmatine-sulfate-oral-clinical\nThere is limited human outcome evidence, with substantial attrition to consider.\nA randomized trial of 2.670 g/day oral agmatine sulfate for 14 days reported greater pain and quality-of-life improvements than placebo; 51 and 48 were randomized, but 31 and 30 were analyzed.\nModel: Lumbar disc-associated radiculopathy; double-blind placebo-controlled trial after dose escalation.\nLimitations: Short exposure and reduced analyzed sample limit inference; molecular mediation and general chronic-pain efficacy were not established.\nEvidence access: Primary abstract\nSafety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20447305/ · DOI 10.1111/j.1526-4637.2010.00808.x","model_system":"Lumbar disc-associated radiculopathy; double-blind placebo-controlled trial after dose escalation.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e0426971-7d13-51c9-8354-6547b664f1cf","stable_key":"import-220adaab-10d8-5c4e-a3f5-a48700ea794d","title":"Agmatine Sulfate: transport, guanidino metabolism, ion channels and cross-nutrient mechanisms (2026-09-20)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"b55d70e22d07b80964f825770d92fdd1745221420ed8af8d94ca5182b9994509","revision_id":"fc7be029-20e0-5943-b74e-3b06ba694571","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}